Stock Market & Financial Investment News

News Breaks February 22, 2013 06:17 EDT BCR C.R. Bard downgraded to Sell from Neutral at Goldman Goldman downgraded C.R. Bard to reflect increasing competitive pressures, reinvestment activity, and lowered assumptions for its peripheral drug eluting balloon. Price target lowered to $95 from $99. News For BCR From The Last 14 Days Check below for free stories on BCR the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 13, 2013 17:08 EDT BCR C.R. Bard to pay $48.26M to U.S to resolve false claims act accusations Subscribe for More Information May 8, 2013 07:38 EDT BCR BofA/Merrill's medical tech analyst hold an analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.